Details for New Drug Application (NDA): 208276
✉ Email this page to a colleague
NDA 208276 describes REMODULIN, which is a drug marketed by United Therap and is included in two NDAs. It is available from one supplier. There are ten patents protecting this drug and two Paragraph IV challenges. Additional details are available on the REMODULIN profile page.
The generic ingredient in REMODULIN is treprostinil. There are nineteen drug master file entries for this compound. Six suppliers are listed for this compound. Additional details are available on the treprostinil profile page.
The generic ingredient in REMODULIN is treprostinil. There are nineteen drug master file entries for this compound. Six suppliers are listed for this compound. Additional details are available on the treprostinil profile page.
Summary for 208276
| Tradename: | REMODULIN |
| Applicant: | United Therap |
| Ingredient: | treprostinil |
| Patents: | 4 |
Profile for product number 001
| Active Rx/OTC/Discontinued: | DISCN | Dosage: | SOLUTION;INTRAVENOUS, SUBCUTANEOUS | Strength | 20MG/20ML (1MG/ML) | ||||
| Approval Date: | Jul 30, 2018 | TE: | RLD: | No | |||||
| Patent: | ⤷ Sign Up | Patent Expiration: | Dec 16, 2024 | Product Flag? | Y | Substance Flag? | Delist Request? | ||
| Patent: | ⤷ Sign Up | Patent Expiration: | Dec 15, 2028 | Product Flag? | Substance Flag? | Y | Delist Request? | ||
| Patent: | ⤷ Sign Up | Patent Expiration: | Dec 15, 2028 | Product Flag? | Substance Flag? | Y | Delist Request? | Y | |
Complete Access Available with Subscription
